Nurcombe V - Search Results

1

Proteomics of breast cancer for marker discovery and signal pathway profiling.

Hondermarck H, Vercoutter-Edouart AS, Révillion F, Lemoine J, el-Yazidi-Belkoura I, Nurcombe V, Peyrat JP. Hondermarck H, et al. Among authors: nurcombe v. Proteomics. 2001 Oct;1(10):1216-32. doi: 10.1002/1615-9861(200110)1:10<1216::AID-PROT1216>3.0.CO;2-P. Proteomics. 2001. PMID: 11721634 Review.

2

Proteomics of breast cancer: outcomes and prospects.

El Yazidi-Belkoura I, Adriaenssens E, Vercoutter-Edouart AS, Lemoine J, Nurcombe V, Hondermarck H. El Yazidi-Belkoura I, et al. Among authors: nurcombe v. Technol Cancer Res Treat. 2002 Aug;1(4):287-96. doi: 10.1177/153303460200100410. Technol Cancer Res Treat. 2002. PMID: 12625788 Free article. Review.

3

The mitogenic signaling pathway for fibroblast growth factor-2 involves the tyrosine phosphorylation of cyclin D2 in MCF-7 human breast cancer cells.

Vercoutter-Edouart A, Lemoine J, Smart CE, Nurcombe V, Boilly B, Peyrat J, Hondermarck H. Vercoutter-Edouart A, et al. Among authors: nurcombe v. FEBS Lett. 2000 Aug 4;478(3):209-15. doi: 10.1016/s0014-5793(00)01855-x. FEBS Lett. 2000. PMID: 10930570 Free article.

4

Proteomic analysis reveals that 14-3-3sigma is down-regulated in human breast cancer cells.

Vercoutter-Edouart AS, Lemoine J, Le Bourhis X, Louis H, Boilly B, Nurcombe V, Révillion F, Peyrat JP, Hondermarck H. Vercoutter-Edouart AS, et al. Among authors: nurcombe v. Cancer Res. 2001 Jan 1;61(1):76-80. Cancer Res. 2001. PMID: 11196201

5

Nerve growth factor overexpression and autocrine loop in breast cancer cells.

Dollé L, El Yazidi-Belkoura I, Adriaenssens E, Nurcombe V, Hondermarck H. Dollé L, et al. Among authors: nurcombe v. Oncogene. 2003 Aug 28;22(36):5592-601. doi: 10.1038/sj.onc.1206805. Oncogene. 2003. PMID: 12944907

6

Nerve growth factor receptors and signaling in breast cancer.

Dollé L, Adriaenssens E, El Yazidi-Belkoura I, Le Bourhis X, Nurcombe V, Hondermarck H. Dollé L, et al. Among authors: nurcombe v. Curr Cancer Drug Targets. 2004 Sep;4(6):463-70. doi: 10.2174/1568009043332853. Curr Cancer Drug Targets. 2004. PMID: 15379632 Review.

7

FGF signals for cell proliferation and migration through different pathways.

Boilly B, Vercoutter-Edouart AS, Hondermarck H, Nurcombe V, Le Bourhis X. Boilly B, et al. Among authors: nurcombe v. Cytokine Growth Factor Rev. 2000 Dec;11(4):295-302. doi: 10.1016/s1359-6101(00)00014-9. Cytokine Growth Factor Rev. 2000. PMID: 10959077 Review.

8

Nerve growth factor stimulates proliferation and survival of human breast cancer cells through two distinct signaling pathways.

Descamps S, Toillon RA, Adriaenssens E, Pawlowski V, Cool SM, Nurcombe V, Le Bourhis X, Boilly B, Peyrat JP, Hondermarck H. Descamps S, et al. Among authors: nurcombe v. J Biol Chem. 2001 May 25;276(21):17864-70. doi: 10.1074/jbc.M010499200. Epub 2001 Feb 28. J Biol Chem. 2001. PMID: 11359788 Free article.

9

Nerve growth factor is a potential therapeutic target in breast cancer.

Adriaenssens E, Vanhecke E, Saule P, Mougel A, Page A, Romon R, Nurcombe V, Le Bourhis X, Hondermarck H. Adriaenssens E, et al. Among authors: nurcombe v. Cancer Res. 2008 Jan 15;68(2):346-51. doi: 10.1158/0008-5472.CAN-07-1183. Cancer Res. 2008. PMID: 18199526

10

Bringing Heparan Sulfate Glycomics Together with Proteomics for the Design of Novel Therapeutics: A Historical Perspective.

Nurcombe V, Ling L, Hondermarck H, Cool SM, Smith RAA. Nurcombe V, et al. Proteomics. 2019 Nov;19(21-22):e1800466. doi: 10.1002/pmic.201800466. Epub 2019 Jul 3. Proteomics. 2019. PMID: 31197945 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

158 results

Search Page

Filters